Armata Pharmaceuticals (ARMP) Gains from Investment Securities (2015 - 2026)
Armata Pharmaceuticals (ARMP) posted Gains from Investment Securities of $20.6 million for Q1 2026, up 9590.14% sequentially from $213000.0 in Q1 2015.
Armata Pharmaceuticals (ARMP) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Gains from Investment Securities for 2 years, with the latest figure at $20.6 million in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (changed N/A YoY) and the FY2013 annual result came in at $759000.0, changed N/A from the prior year.
- Gains from Investment Securities rose to $20.6 million in Q1 2026 per ARMP's latest filing, from $213000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $20.6 million in Q1 2026 and troughed at $20.6 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.64 Mn |
| Mar 31, 2026 | 20.64 Mn |
| Mar 31, 2015 | 213,000.00 |
| Mar 31, 2015 | 213,000.00 |